An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF)

Trial Profile

An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Extracorporeal hepatocyte-based therapy (Primary)
  • Indications Liver failure
  • Focus Therapeutic Use
  • Sponsors Vital Therapies
  • Most Recent Events

    • 20 Oct 2015 According to ClinicalTrials.gov, this trial has been terminated because of the results from the 1st pivotal study, the ELAD clinical plan in being re-evaluated.
    • 20 Oct 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 30 Jul 2015 According to a Vital Therapies media release, the seventh patient has been enrolled in this trial as of 29 July 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top